Market Access | Getting therapies in patients' hands

News

Trump raises spectre of drug pricing mandates for Medicare

CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry.

News

Novo Nordisk gets FDA okay for Wegovy pill

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.

News

Nine more companies sign pricing deals with Trump

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

Market Access

Women's health: Predictions for 2026

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

News

Two boxes and bottles of Rybrevant Faspro

J&J's subcutaneous Rybrevant cleared by FDA

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

News

Pharma’s Medicare counteroffers are all in, says HHS

On the heels of a setback in pharma’s legal attempts to block Medicare’s new medicine price negotiation powers, the US government has said all drugmakers whose products ar

News

NICE backs frontline use of Jemperli in endometrial cancer

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w

News

Trump raises spectre of drug pricing mandates for Medicare

CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry.

News

Novo Nordisk gets FDA okay for Wegovy pill

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.

Press Releases

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

News

Immunocore's rare eye cancer drug backed by NICE

Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position.

Views & Analysis

Market Access

Women's health: Predictions for 2026

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

Market Access

Images of pills on dominoes pieces, one being removed from the line

UK pharma policy at a turning point: NICE threshold reform, ...

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

Deep Dive

Market Access

Will MFN drug pricing help patients – or hurt access?

Market Access

Inside Merck’s push to future-proof health systems

Market Access

EVERSANA leaders on digital-first models, affordability, and...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Market Access

pharmaphorum podcast Episode 210 - Neal Masia

Smoothing a contract pathway through uncertainty: In convers...

Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.

Market Access

Frontiers Health limited podcast series, Pilar Fernández Hermida

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.

Video

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

Market Access

Interview at BIO 2025 with Paul Romness and Farah Ahmad

Global unity in the face of uncertainty, with Paul Romness a...

Market Access

Interview at BIO 2025 with Kyle Touchstone and Laura Rowley

Biotech opportunities in North Carolina, with Kyle Touchston...

From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access

Partner Content

Measuring Patient Engagement Summit Europe

The World’s Only Patient Engagement Measurement Summit is coming to Europe!

Market Access

Partner Content

The Inaugural Market Access for CNS Therapeutics Summit Has ...

The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access

Partner Content

The 2nd Cell & Gene Therapy Regulatory Affairs Summit Return...

Navigate FDA changes & global alignment at the only CGT regulatory strategy summit.

Trump raises spectre of drug pricing mandates for Medicare

Novo Nordisk gets FDA okay for Wegovy pill

Nine more companies sign pricing deals with Trump

Women's health: Predictions for 2026

J&J's subcutaneous Rybrevant cleared by FDA

Surprise Enhertu rejection follows NICE process change

Pharma’s Medicare counteroffers are all in, says HHS

NICE backs frontline use of Jemperli in endometrial cancer

Trump raises spectre of drug pricing mandates for Medicare

Novo Nordisk gets FDA okay for Wegovy pill

VuuAI and Amiculum partner to transform content engagement i...

Immunocore's rare eye cancer drug backed by NICE

Women's health: Predictions for 2026

UK pharma policy at a turning point: NICE threshold reform, ...

Will MFN drug pricing help patients – or hurt access?

Inside Merck’s push to future-proof health systems

EVERSANA leaders on digital-first models, affordability, and...

Innovative Medicines Fund and the opportunity for ICSs to mo...

Medical Informatics and Rare Disease: a bridge between two w...

ICSs - an opportunity to improve Patient & Market Access at ...

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Smoothing a contract pathway through uncertainty: In convers...

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

Consolidating data strategy for global success: Insights fro...

Global unity in the face of uncertainty, with Paul Romness a...

Biotech opportunities in North Carolina, with Kyle Touchston...

Life Sciences Industry Report 2025

Navigating Routes to Commercial Excellence in Cell and Gene ...

Pricing & Market Access Outlook 2015/2016 Edition

Targeted Therapies Partnering & Licensing Summit Asia

Measuring Patient Engagement Summit Europe

The Inaugural Market Access for CNS Therapeutics Summit Has ...

Innovative contracting in Europe – a Trojan horse?

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

VuuAI and Amiculum partner to transform content engagement i...

Targeted Therapies Partnering & Licensing Summit Asia

The 2nd Cell & Gene Therapy Regulatory Affairs Summit Return...

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks